USH2246H1 - Method for analyzing continuous glucose monitoring data - Google Patents

Method for analyzing continuous glucose monitoring data Download PDF

Info

Publication number
USH2246H1
USH2246H1 US11/713,965 US71396507A USH2246H US H2246 H1 USH2246 H1 US H2246H1 US 71396507 A US71396507 A US 71396507A US H2246 H USH2246 H US H2246H
Authority
US
United States
Prior art keywords
blood glucose
curve
patient
glucose levels
cgms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/713,965
Inventor
Michael Franklin Miller
Poul Strange
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Priority to US11/713,965 priority Critical patent/USH2246H1/en
Assigned to SANOFI-AVENTIS U.S. LLC reassignment SANOFI-AVENTIS U.S. LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MILLER, MICHAEL FRANKLIN, STRANGE, POUL
Assigned to SANOFI-AVENTIS reassignment SANOFI-AVENTIS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SANOFI-AVENTIS U.S. LLC.
Application granted granted Critical
Publication of USH2246H1 publication Critical patent/USH2246H1/en
Assigned to SANOFI reassignment SANOFI CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SANOFI-AVENTIS
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Definitions

  • the present invention relates, generally, to methods for analyzing continuous glucose monitoring data. More specifically, the invention relates to methods for determining a patient's susceptibility to hypoglycemic events and methods for predicting the effectiveness of insulin therapy in lowering average blood glucose levels in a diabetic patient.
  • Diabetics must monitor their own blood glucose levels, often several times a day, to determine how far above or below a normal level their glucose level is and to determine what oral medications or insulin(s) they may need. This is often done by placing a drop of blood from a skin prick onto a glucose strip and then inserting the strip into a glucose meter, which is a small machine that provides a digital readout of the blood glucose level.
  • CGMS continuous glucose monitoring systems
  • these devices work by inserting a small sensor into subcutaneous tissues.
  • the sensor measures the level of glucose in the tissue and sends this information to a monitor worn by the patient which stores the results.
  • the monitor In order to determine blood glucose levels, the monitor must be calibrated daily by entering at least three blood glucose readings obtained at different times, using a standard blood glucose meter.
  • Medtronic, Inc. of Minneapolis, Minn. sells an approved MinMed® device which can provide up to 288 glucose measurements every 24 hours for up to 72 hours.
  • the glucose level data obtained from continuous glucose monitoring systems is that there is a lot of variability in the data.
  • the glucose level data shows a lot of sharp fluctuations, or signal noise, that is most likely not indicative of the average blood glucose levels, but rather is likely due to variability in the measurements.
  • One aspect of the present invention relates to a method for predicting the effectiveness of medication-based therapy in lowering average blood glucose levels in a diabetic patient comprising the steps of: measuring the patient's blood glucose levels continuously for a period of time to obtain blood glucose level data; applying a Fourier approximation to develop a continuous oscillating blood glucose curve approximately representing the blood glucose level data; mathematically decomposing oscillation of the blood glucose curve into at least one respective component harmonic curve; calculating an amplitude of a composite curve that is a function of the at least one respective component harmonic curve; and correlating the amplitude of the composite curve with an expectation that medication-based therapy will lower the average blood glucose levels in a diabetic patient.
  • This method may further comprise selectively recommending a medication-based therapy on the basis of the arithmetic average of the relative minima.
  • Another aspect of the invention is a method for determining susceptibility to symptomatic hypoglycemia in a patient comprising the steps of: measuring the patient's blood glucose levels continuously for a period of time to obtain blood glucose level data; applying a Fourier approximation to develop a continuous oscillating blood glucose curve approximately representing the blood glucose level data; identifying areas of the curve having steepest descent, the areas of steepest descent corresponding to relative minima of a first derivative of the curve; calculating an arithmetic average of the relative minima; and correlating a high arithmetic average of the relative minima with an increased susceptibility to symptomatic hypoglycemia.
  • This method may further comprise selectively recommending a medication-based therapy on the basis of the arithmetic average of the relative minima.
  • Another aspect of the invention is a device for continuously monitoring blood glucose levels in a patient comprising: a sensor for measuring blood glucose levels in said patient; a monitor for recording blood glucose levels at regular intervals; and software executable by said monitor for applying a Fourier approximation to said blood glucose levels.
  • FIG. 1A shows an exemplary graph of blood glucose level data from an exemplary type 2 diabetes mellitus patient using a CGMS sensor.
  • the graph also shows a Fourier approximation (5 cycles) of the blood glucose level data and the error between the blood glucose level data and the Fourier approximation.
  • FIG. 1B shows an exemplary graph of blood glucose levels from an exemplary type 2 diabetes mellitus patient using a CGMS sensor.
  • the graph also shows a Fourier approximation (20 cycles) of the blood glucose level data and the error between the blood glucose level data and the Fourier approximation.
  • FIG. 2 shows an exemplary graph of the mean Fourier approximations (7 cycles) of the blood glucose levels of exemplary type 1 diabetes mellitus patients, exemplary type 2 diabetes mellitus patients, exemplary normal subjects, and exemplary type 1 diabetes mellitus patients using an insulin pump.
  • FIG. 3 shows an exemplary graph of the mean blood glucose levels from exemplary type 1 diabetes mellitus patients using a CGMS sensor along with the first, the sum of the second and third, and the sum of the fourth and higher harmonic functions of a Fourier approximation of the mean blood glucose level data.
  • FIG. 4 shows an exemplary graph of week twenty-four HbA1c levels versus the mean baseline amplitude of the sum of the second and third harmonic functions of a Fourier approximation.
  • FIG. 5 shows an exemplary graph of rate of hypoglycemic events versus baseline average steepest descent from a Fourier approximation (3 cycles) of mean blood glucose level data from exemplary pediatric patients with type 1 diabetes mellitus treated with Lantus® (insulin glargine) manufactured and distributed by sanofi-aventis and a control medication.
  • Lantus® insulin glargine
  • the present invention relates, generally, to methods for analyzing continuous glucose monitoring data.
  • applicants have applied the Fourier approximation method to patient CGMS data.
  • the Fourier approximation method provides a statistical model for assessing a patient's whole blood glucose profile over a period of time.
  • the Fourier approximation method results in the smoothing out of extraneous variability in the CGMS data via dimension reduction.
  • the Fourier approximation method can be applied to blood glucose levels in the following manner.
  • levels of blood glucose over a given period of time can be defined as the function CGMS(t).
  • the Fourier approximation of the function CGMS(t) can be designated as FR(t
  • k) where CGMS(t) FR(t
  • Individual components of the Fourier approximation can be used to measure the clinical outcomes for the treatment of hypoglycemia or diabetes. For example, if the clinical outcome is reducing the blood glucose levels, one would measure the first term in the Fourier expansion, the twenty-four hour mean blood glucose level. Similarly, if the goal is to reduce the risk of hypoglycemic and hyperglycemic events, one would measure the harmonic amplitudes. Furthermore, the CGMS twenty-four hour standard deviation is proportional to the square root of the sum of the squares of the individual amplitudes of all component harmonic functions. Thus, a reduction of the standard deviation of CGMS levels can be measured by a reduction of the Fourier harmonic component amplitudes.
  • FIG. 1A shows a Fourier approximation of the CGMS data using five cycles calculated as described above.
  • FIG. 1B shows a Fourier approximation of the same data using twenty cycles.
  • the Fourier approximations tend to smooth out the high-frequency noise observed in the raw CGMS data.
  • the Fourier approximation does a better job of approximating the actual CGMS data as shown by the decrease in the fluctuation of the error graph in FIG. 1B as compared to FIG. 1 A.
  • the smoothness of the Fourier approximation curve is decreased, resulting in a curve that is less likely to be useful in identifying prognostic indicators.
  • a seven cycle Fourier approximation is applied to twenty-four hour CGMS data.
  • An aggregate curve is created for each patient population by averaging the subject Fourier coefficients and producing a graph determined by these averages.
  • FIG. 2 shows the resulting graphs for each patient population.
  • T1DM type 1 diabetes mellitus
  • N 90; half of the patients are on a typical insulin therapy regimen while half of the patients are using Lantus®.
  • a Fourier approximation is applied to twenty-four hour CGMS data.
  • An aggregate curve is created for the patient population by averaging the subject Fourier coefficients and producing a graph determined by these averages.
  • the Fourier approximation is decomposed into its component harmonics.
  • FIG. 3 shows the resulting graph of the mean blood glucose levels from the patient population along with the first, the sum of the second and third, and the sum of the fourth and higher harmonic functions of the aggregate Fourier approximation.
  • FIG. 4 shows a graph of week twenty-four HbA1c levels versus the mean baseline amplitude of the sum of the second and third harmonic functions of a Fourier approximation.
  • HbA1c is a specific subtype of hemoglobin A. Hemoglobin A comprises about 90% of the total hemoglobin in red blood cells. When glucose binds to hemoglobin A, it forms the A1c subtype. This reaction and the reverse reaction, or decomposition, proceeds relatively slowly, so any buildup persists for roughly four weeks. As a result, the HbAlc level correlates very well with the average blood glucose level of approximately the past 4 weeks. In normal subjects, the HbAlc reach a steady state of about 4 to 5% of the hemoglobin being the A1c subtype. Accordingly, the HbA1c level is a good proxy of average blood glucose levels.
  • FIG. 4 shows a correlation between the amplitude of the sum of the second and third harmonic functions of a Fourier approximation in type 1 diabetic patients with week 24 HbA1c levels.
  • higher amplitude of the sum of the 2nd and 3rd harmonic functions (a composite curve) at baseline predicted higher week twenty-four HbA1C values in pediatric patients with T1DM.
  • the amplitude of the sum of the second and third harmonic functions of a Fourier approximation may be useful in predicting the effectiveness of medication-based therapy in lowering average blood glucose levels in a type 1 diabetic patient.
  • This correlation may be used, for example, as a basis for selectively recommending a medication-based therapy on the basis of the amplitude of the composite curve, e.g. to recommend the medication-based therapy if the amplitude exceeds a predetermined, empirically set, amplitude threshold.
  • the threshold and decision-based logic may be implemented by software executable by a special-purpose CGMS device configured in accordance with the present invention or a conventional personal computer (collectively, a “PC”), and the recommendation may be textual, graphical or other indicia displayed on a display screen of the PC, etc. to a prescribing physician, etc.
  • T1DM type 1 diabetes mellitus
  • N 90; half of the patients are on a typical insulin therapy regimen while half of the patients are using Lantus®.
  • Fourier approximation using 3 cycles is applied to a 24-hour CGMS profile.
  • the areas of the curve having the steepest descent are identified, the areas of steepest descent corresponding to the relative minima of a first derivative of the curve (e.g., as determined by zeros of the second derivative of the curve).
  • the average steepest descent is calculated by mathematically calculating the arithmetic average of the relative minima.
  • FIG. 5 shows the resulting graph of the rate of hypoglycemic events in both the control and Lantus® populations versus the baseline average steepest descent as described above.
  • the average steepest descent at baseline has an association with symptomatic hypoglycemia (with BG ⁇ 50 mg/dL).
  • baseline steep descent of blood glucose levels may increase the risk of hypoglycemia at certain times in pediatric patients with T1DM.
  • the average steepest descent of Fourier approximations of CGMS data may be useful for determining susceptibility to symptomatic hypoglycemia in a patient.
  • This determination for susceptibility may be used, for example, as a basis for selectively recommending a medication-based therapy on the basis of the arithmetic average of the relative minima, e.g. to recommend the medication-based therapy if the average exceeds a predetermined, empirically set, average threshold.
  • the threshold and decision- based logic may be implemented by software executable by a special-purpose CGMS device configured in accordance with the present invention, a conventional personal computer (collectively, a “PC”), and the recommendation may be textual, graphical or other indicia displayed on a display screen of the PC, etc. to a prescribing physician, etc.
  • a device for continuously monitoring blood glucose levels in a patient may include a conventional sensor for measuring blood glucose levels in the patient and a conventional monitor for recording blood glucose levels at regular intervals.
  • a substantially conventional CGMS device may be specially configured in accordance with the present invention to include software executable by the monitor for applying a Fourier approximation to the blood glucose level data, determining composite harmonic curve amplitudes, determining average steepest descent, determining susceptibility to symptomatic hypoglycemia, storing threshold data, selectively recommending medication-based therapy as a function of a relationship to stored threshold data, etc., as discussed in greater detail above.
  • the device may be capable of exporting gathered data to a personal computer or other external computing device configured with similar specially configured software for providing such functionality.

Abstract

A method for predicting the effectiveness of medication-based therapy in lowering average blood glucose levels in a diabetic patient is provided. This method may further comprise selectively recommending a medication-based therapy on the basis of the arithmetic average of the relative minima. A method for determining susceptibility to symptomatic hypoglycemia in a patient is provided. This method may further comprise selectively recommending a medication-based therapy on the basis of the arithmetic average of the relative minima. Provided also is a device for continuously monitoring blood glucose levels in a patient. The methods and device involve applying a Fourier approximation to blood glucose level data.

Description

CROSS REFERENCE TO RELATED APPLICATIONS
This application is related to U.S. application Ser. No. 60/863,673, filed Oct. 31, 2006, the entire disclosure of which is hereby incorporated herein by reference.
FIELD OF INVENTION
The present invention relates, generally, to methods for analyzing continuous glucose monitoring data. More specifically, the invention relates to methods for determining a patient's susceptibility to hypoglycemic events and methods for predicting the effectiveness of insulin therapy in lowering average blood glucose levels in a diabetic patient.
BACKGROUND OF INVENTION
Diabetics must monitor their own blood glucose levels, often several times a day, to determine how far above or below a normal level their glucose level is and to determine what oral medications or insulin(s) they may need. This is often done by placing a drop of blood from a skin prick onto a glucose strip and then inserting the strip into a glucose meter, which is a small machine that provides a digital readout of the blood glucose level.
Recently, continuous glucose monitoring systems (CGMS) have been developed that continuously record a patient's glucose levels throughout the day. Generally speaking, these devices work by inserting a small sensor into subcutaneous tissues. The sensor measures the level of glucose in the tissue and sends this information to a monitor worn by the patient which stores the results, In order to determine blood glucose levels, the monitor must be calibrated daily by entering at least three blood glucose readings obtained at different times, using a standard blood glucose meter. For example, Medtronic, Inc. of Minneapolis, Minn., sells an approved MinMed® device which can provide up to 288 glucose measurements every 24 hours for up to 72 hours.
One problem with the blood glucose level data obtained from continuous glucose monitoring systems is that there is a lot of variability in the data. The glucose level data shows a lot of sharp fluctuations, or signal noise, that is most likely not indicative of the average blood glucose levels, but rather is likely due to variability in the measurements.
Because of the lack of accurate diary data from patients and the lack of mealtime synchronization, another problem with CGMS data is the inability to aggregate the data easily to facilitate treatment group comparisons and to visualize the average treatment group curves.
As a result of the problems indicated above, a further problem is the lack of CGMS data indicators that would be useful for diagnosing and treating hypoglycemia and diabetes.
Therefore, there is a need to aggregate continuous blood glucose level data and to identify prognostic indicators for diagnosing and treating hypoglycemia and diabetes.
SUMMARY OF THE INVENTION
One aspect of the present invention relates to a method for predicting the effectiveness of medication-based therapy in lowering average blood glucose levels in a diabetic patient comprising the steps of: measuring the patient's blood glucose levels continuously for a period of time to obtain blood glucose level data; applying a Fourier approximation to develop a continuous oscillating blood glucose curve approximately representing the blood glucose level data; mathematically decomposing oscillation of the blood glucose curve into at least one respective component harmonic curve; calculating an amplitude of a composite curve that is a function of the at least one respective component harmonic curve; and correlating the amplitude of the composite curve with an expectation that medication-based therapy will lower the average blood glucose levels in a diabetic patient. This method may further comprise selectively recommending a medication-based therapy on the basis of the arithmetic average of the relative minima.
Another aspect of the invention is a method for determining susceptibility to symptomatic hypoglycemia in a patient comprising the steps of: measuring the patient's blood glucose levels continuously for a period of time to obtain blood glucose level data; applying a Fourier approximation to develop a continuous oscillating blood glucose curve approximately representing the blood glucose level data; identifying areas of the curve having steepest descent, the areas of steepest descent corresponding to relative minima of a first derivative of the curve; calculating an arithmetic average of the relative minima; and correlating a high arithmetic average of the relative minima with an increased susceptibility to symptomatic hypoglycemia. This method may further comprise selectively recommending a medication-based therapy on the basis of the arithmetic average of the relative minima.
Another aspect of the invention is a device for continuously monitoring blood glucose levels in a patient comprising: a sensor for measuring blood glucose levels in said patient; a monitor for recording blood glucose levels at regular intervals; and software executable by said monitor for applying a Fourier approximation to said blood glucose levels.
BRIEF DESCRIPTION OF DRAWINGS
FIG. 1A shows an exemplary graph of blood glucose level data from an exemplary type 2 diabetes mellitus patient using a CGMS sensor. The graph also shows a Fourier approximation (5 cycles) of the blood glucose level data and the error between the blood glucose level data and the Fourier approximation.
FIG. 1B shows an exemplary graph of blood glucose levels from an exemplary type 2 diabetes mellitus patient using a CGMS sensor. The graph also shows a Fourier approximation (20 cycles) of the blood glucose level data and the error between the blood glucose level data and the Fourier approximation.
FIG. 2 shows an exemplary graph of the mean Fourier approximations (7 cycles) of the blood glucose levels of exemplary type 1 diabetes mellitus patients, exemplary type 2 diabetes mellitus patients, exemplary normal subjects, and exemplary type 1 diabetes mellitus patients using an insulin pump.
FIG. 3 shows an exemplary graph of the mean blood glucose levels from exemplary type 1 diabetes mellitus patients using a CGMS sensor along with the first, the sum of the second and third, and the sum of the fourth and higher harmonic functions of a Fourier approximation of the mean blood glucose level data.
FIG. 4 shows an exemplary graph of week twenty-four HbA1c levels versus the mean baseline amplitude of the sum of the second and third harmonic functions of a Fourier approximation.
FIG. 5 shows an exemplary graph of rate of hypoglycemic events versus baseline average steepest descent from a Fourier approximation (3 cycles) of mean blood glucose level data from exemplary pediatric patients with type 1 diabetes mellitus treated with Lantus® (insulin glargine) manufactured and distributed by sanofi-aventis and a control medication.
 DETAILED DESCRIPTION
The present invention relates, generally, to methods for analyzing continuous glucose monitoring data. In order to minimize the impact of sharp fluctuations in CGMS data and to have the ability to aggregate CGMS data from various patient populations, applicants have applied the Fourier approximation method to patient CGMS data.
The Fourier approximation method provides a statistical model for assessing a patient's whole blood glucose profile over a period of time. The Fourier approximation method results in the smoothing out of extraneous variability in the CGMS data via dimension reduction. By applying a Fourier approximation to CGMS data, one can separate the blood glucose profile into a mean level and variability components which can be further partitioned into component harmonics.
The Fourier approximation method can be applied to blood glucose levels in the following manner. For example, levels of blood glucose over a given period of time can be defined as the function CGMS(t). The Fourier approximation of the function CGMS(t) can be designated as FR(t|k) where CGMS(t)=FR(t|k). Where t is measured in hours and ranges from 0 to 24 and harmonic term i oscillates through exactly i cycles in 24 hours, the Fourier approximation is calculated as follows:
=μ+ΣiAMP(i)cos(2πi (t−PHS (i))/24)
=μ+Σi{A(i)cos(2πi t/24)+B(i)sin(2πi t/24)}
where
μ=CGMS 24-hour mean=AUC/24
A(i), B(i) regression coefficients for cycle i, i=l to k
Amplitude of harmonic term i=sqrt(A(i)2+B(i)2)
Phase shift for harmonic term i=arctan(B(i)/A(i))
Individual components of the Fourier approximation can be used to measure the clinical outcomes for the treatment of hypoglycemia or diabetes. For example, if the clinical outcome is reducing the blood glucose levels, one would measure the first term in the Fourier expansion, the twenty-four hour mean blood glucose level. Similarly, if the goal is to reduce the risk of hypoglycemic and hyperglycemic events, one would measure the harmonic amplitudes. Furthermore, the CGMS twenty-four hour standard deviation is proportional to the square root of the sum of the squares of the individual amplitudes of all component harmonic functions. Thus, a reduction of the standard deviation of CGMS levels can be measured by a reduction of the Fourier harmonic component amplitudes.
EXAMPLES Example 1
A Fourier approximation is applied to the observed CGMS blood glucose data for one patient with type 2 diabetes mellitus. FIG. 1A shows a Fourier approximation of the CGMS data using five cycles calculated as described above. FIG. 1B shows a Fourier approximation of the same data using twenty cycles. As seen in the FIGS. 1A and 1B, the Fourier approximations tend to smooth out the high-frequency noise observed in the raw CGMS data. As one increases the number of cycles, the Fourier approximation does a better job of approximating the actual CGMS data as shown by the decrease in the fluctuation of the error graph in FIG. 1B as compared to FIG. 1A. As one increases the number of cycles, however, the smoothness of the Fourier approximation curve is decreased, resulting in a curve that is less likely to be useful in identifying prognostic indicators.
Example 2
This study employs CGMS 24-hour blood glucose profiles from the following patient populations:
    • pediatric patients with type 1 diabetes mellitus (T1DM), N=90;
    • adult patients with type 2 diabetes mellitus (T2DM), N=34;
    • normal subjects, N=15; and
    • patients with T1DM using an insulin pump, N=37.
For each subject, a seven cycle Fourier approximation is applied to twenty-four hour CGMS data. An aggregate curve is created for each patient population by averaging the subject Fourier coefficients and producing a graph determined by these averages. FIG. 2 shows the resulting graphs for each patient population. An interesting observation is that insulin-pump therapy not only reduces the average blood glucose levels but also reduces the amplitude of the resulting aggregate Fourier approximation. This indicates that type 1 patients using the insulin pump are less likely to experience hypoglycemic and hyperglycemic events.
Example 3
This study employs CGMS 24-hour blood glucose profiles from the pediatric patients with type 1 diabetes mellitus (T1DM), N=90; half of the patients are on a typical insulin therapy regimen while half of the patients are using Lantus®. For each subject, a Fourier approximation is applied to twenty-four hour CGMS data. An aggregate curve is created for the patient population by averaging the subject Fourier coefficients and producing a graph determined by these averages. The Fourier approximation is decomposed into its component harmonics. FIG. 3 shows the resulting graph of the mean blood glucose levels from the patient population along with the first, the sum of the second and third, and the sum of the fourth and higher harmonic functions of the aggregate Fourier approximation.
FIG. 4 shows a graph of week twenty-four HbA1c levels versus the mean baseline amplitude of the sum of the second and third harmonic functions of a Fourier approximation. HbA1c is a specific subtype of hemoglobin A. Hemoglobin A comprises about 90% of the total hemoglobin in red blood cells. When glucose binds to hemoglobin A, it forms the A1c subtype. This reaction and the reverse reaction, or decomposition, proceeds relatively slowly, so any buildup persists for roughly four weeks. As a result, the HbAlc level correlates very well with the average blood glucose level of approximately the past 4 weeks. In normal subjects, the HbAlc reach a steady state of about 4 to 5% of the hemoglobin being the A1c subtype. Accordingly, the HbA1c level is a good proxy of average blood glucose levels.
FIG. 4 shows a correlation between the amplitude of the sum of the second and third harmonic functions of a Fourier approximation in type 1 diabetic patients with week 24 HbA1c levels. For fixed-baseline HbA1C, higher amplitude of the sum of the 2nd and 3rd harmonic functions (a composite curve) at baseline predicted higher week twenty-four HbA1C values in pediatric patients with T1DM. Accordingly, the amplitude of the sum of the second and third harmonic functions of a Fourier approximation (the composite second and third harmonic curve) may be useful in predicting the effectiveness of medication-based therapy in lowering average blood glucose levels in a type 1 diabetic patient.
This correlation may be used, for example, as a basis for selectively recommending a medication-based therapy on the basis of the amplitude of the composite curve, e.g. to recommend the medication-based therapy if the amplitude exceeds a predetermined, empirically set, amplitude threshold. For example, the threshold and decision-based logic may be implemented by software executable by a special-purpose CGMS device configured in accordance with the present invention or a conventional personal computer (collectively, a “PC”), and the recommendation may be textual, graphical or other indicia displayed on a display screen of the PC, etc. to a prescribing physician, etc.
Example 4
This study employs CGMS 24-hour blood glucose profiles from the pediatric patients with type 1 diabetes mellitus (T1DM), N=90; half of the patients are on a typical insulin therapy regimen while half of the patients are using Lantus®. For each patient, Fourier approximation using 3 cycles is applied to a 24-hour CGMS profile. The areas of the curve having the steepest descent are identified, the areas of steepest descent corresponding to the relative minima of a first derivative of the curve (e.g., as determined by zeros of the second derivative of the curve). The average steepest descent is calculated by mathematically calculating the arithmetic average of the relative minima.
FIG. 5 shows the resulting graph of the rate of hypoglycemic events in both the control and Lantus® populations versus the baseline average steepest descent as described above. As FIG. 5 indicates, the average steepest descent at baseline has an association with symptomatic hypoglycemia (with BG<50 mg/dL). Thus, baseline steep descent of blood glucose levels may increase the risk of hypoglycemia at certain times in pediatric patients with T1DM. Accordingly, the average steepest descent of Fourier approximations of CGMS data may be useful for determining susceptibility to symptomatic hypoglycemia in a patient.
This determination for susceptibility may be used, for example, as a basis for selectively recommending a medication-based therapy on the basis of the arithmetic average of the relative minima, e.g. to recommend the medication-based therapy if the average exceeds a predetermined, empirically set, average threshold. For example, the threshold and decision- based logic may be implemented by software executable by a special-purpose CGMS device configured in accordance with the present invention, a conventional personal computer (collectively, a “PC”), and the recommendation may be textual, graphical or other indicia displayed on a display screen of the PC, etc. to a prescribing physician, etc.
A device for continuously monitoring blood glucose levels in a patient may include a conventional sensor for measuring blood glucose levels in the patient and a conventional monitor for recording blood glucose levels at regular intervals. In accordance with the present invention, a substantially conventional CGMS device may be specially configured in accordance with the present invention to include software executable by the monitor for applying a Fourier approximation to the blood glucose level data, determining composite harmonic curve amplitudes, determining average steepest descent, determining susceptibility to symptomatic hypoglycemia, storing threshold data, selectively recommending medication-based therapy as a function of a relationship to stored threshold data, etc., as discussed in greater detail above. By way of further example, the device may be capable of exporting gathered data to a personal computer or other external computing device configured with similar specially configured software for providing such functionality.
While certain of the preferred embodiments of the present invention have been described and specifically exemplified above, it is not intended that the invention be limited to such embodiments. Various modifications may be made thereto without departing from the scope and spirit of the present invention, as set forth in the following claims.

Claims (9)

1. A method implemented on a CGMS device for predicting the effectiveness of medication-based therapy in lowering average blood glucose levels in a diabetic patient comprising the steps of:
measuring by a sensor said patient's blood glucose levels continuously for a period of time to obtain blood glucose level data and providing said measured glucose levels to a CGMS device;
applying by the CGMS device a Fourier approximation to develop a continuous oscillating blood glucose curve approximately representing the blood glucose level data;
mathematically decomposing by the CGMS device oscillation of the blood glucose curve into at least one respective component harmonic curve;
calculating by the CGMS device an amplitude of a composite curve that is a function of the at least one respective component harmonic curve; and
correlating by the CGMS device the amplitude of the composite curve with an expectation that medication-based therapy will lower the average blood glucose levels in a diabetic patient.
2. The method of claim 1, wherein the function of the at least one respective component harmonic curve is a sum of amplitudes of second and third component harmonic curves.
3. The method of claim 1 further comprising selectively recommending a medication-based therapy on the basis of the amplitude of the composite curve.
4. The method of claim 1, wherein said period of time is twenty-four hours.
5. The method of claim 1, wherein said patient has type 1 diabetes mellitus.
6. A method implemented on a CGMS device for determining susceptibility to symptomatic hypoglycemia in a patient comprising the steps of:
measuring by a sensor said patient's blood glucose levels continuously for a period of time to obtain blood glucose level data and providing said measured glucose levels to a CGMS device;
applying by the CGMS device a Fourier approximation to develop a continuous oscillating blood glucose curve approximately representing the blood glucose level data;
identifying by the CGMS device areas of the curve having the steepest descent, the areas of steepest descent corresponding to relative minima of a first derivative of the curve;
calculating by the CGMS device an arithmetic average of the relative minima; and
correlating by the CGMS device a high arithmetic average of the relative minima with an increased susceptibility to symptomatic hypoglycemia.
7. The method of claim 6 further comprising selectively recommending a medication-based therapy on the basis of the arithmetic average of the relative minima.
8. The method of claim 6, wherein said period of time is 24 hours.
9. A device of continuously monitoring blood glucose levels in a patient comprising:
a sensor for measuring blood glucose levels in said patient;
a monitor for recording blood glucose levels at regular intervals; and
software executable by said monitor for applying a Fourier approximation to said blood glucose levels.
US11/713,965 2006-10-31 2007-02-28 Method for analyzing continuous glucose monitoring data Abandoned USH2246H1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/713,965 USH2246H1 (en) 2006-10-31 2007-02-28 Method for analyzing continuous glucose monitoring data

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86367306P 2006-10-31 2006-10-31
US86393706P 2006-11-01 2006-11-01
US11/713,965 USH2246H1 (en) 2006-10-31 2007-02-28 Method for analyzing continuous glucose monitoring data

Publications (1)

Publication Number Publication Date
USH2246H1 true USH2246H1 (en) 2010-08-03

Family

ID=42359017

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/713,965 Abandoned USH2246H1 (en) 2006-10-31 2007-02-28 Method for analyzing continuous glucose monitoring data

Country Status (1)

Country Link
US (1) USH2246H1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110319322A1 (en) * 2008-04-04 2011-12-29 Hygieia, Inc. Systems, Methods and Devices for Achieving Glycemic Balance
RU2477477C1 (en) * 2011-12-29 2013-03-10 ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ ОБРАЗОВАТЕЛЬНОЕ УЧРЕЖДЕНИЕ ВЫСШЕГО ПРОФЕССИОНАЛЬНОГО ОБРАЗОВАНИЯ "НИЖЕГОРОДСКАЯ ГОСУДАРСТВЕННАЯ МЕДИЦИНСКАЯ АКАДЕМИЯ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ И СОЦИАЛЬНОГО РАЗВИТИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ (ГБОУ ВПО "НижГМА" МИНЗДРАВСОЦРАЗВИТИЯ РОССИИ) Method for prediction of life-threatening arrhythmias in patients with type 2 diabetes mellitus suffering chronic cardiac failure
US9119529B2 (en) 2012-10-30 2015-09-01 Dexcom, Inc. Systems and methods for dynamically and intelligently monitoring a host's glycemic condition after an alert is triggered
US11627894B2 (en) * 2014-07-17 2023-04-18 Roche Diabetes Care, Inc. Method and a device for determining a body fluid glucose level of a patient, and a computer program product

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5533509A (en) * 1993-08-12 1996-07-09 Kurashiki Boseki Kabushiki Kaisha Method and apparatus for non-invasive measurement of blood sugar level
US6370407B1 (en) * 1999-07-27 2002-04-09 Tecmed, Incorporated System for improving the sensitivity and stability of optical polarimetric measurements
US6574490B2 (en) * 2001-04-11 2003-06-03 Rio Grande Medical Technologies, Inc. System for non-invasive measurement of glucose in humans
US6650915B2 (en) * 2001-09-13 2003-11-18 Fovioptics, Inc. Non-invasive measurement of blood analytes using photodynamics

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5533509A (en) * 1993-08-12 1996-07-09 Kurashiki Boseki Kabushiki Kaisha Method and apparatus for non-invasive measurement of blood sugar level
US6370407B1 (en) * 1999-07-27 2002-04-09 Tecmed, Incorporated System for improving the sensitivity and stability of optical polarimetric measurements
US6574490B2 (en) * 2001-04-11 2003-06-03 Rio Grande Medical Technologies, Inc. System for non-invasive measurement of glucose in humans
US6650915B2 (en) * 2001-09-13 2003-11-18 Fovioptics, Inc. Non-invasive measurement of blood analytes using photodynamics

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10736562B2 (en) 2008-04-04 2020-08-11 Hygieia, Inc. Systems, methods and devices for achieving glycemic balance
US11826163B2 (en) 2008-04-04 2023-11-28 Hygieia, Inc. Systems, methods and devices for achieving glycemic balance
US20110319322A1 (en) * 2008-04-04 2011-12-29 Hygieia, Inc. Systems, Methods and Devices for Achieving Glycemic Balance
US9220456B2 (en) * 2008-04-04 2015-12-29 Hygieia, Inc. Systems, methods and devices for achieving glycemic balance
RU2477477C1 (en) * 2011-12-29 2013-03-10 ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ ОБРАЗОВАТЕЛЬНОЕ УЧРЕЖДЕНИЕ ВЫСШЕГО ПРОФЕССИОНАЛЬНОГО ОБРАЗОВАНИЯ "НИЖЕГОРОДСКАЯ ГОСУДАРСТВЕННАЯ МЕДИЦИНСКАЯ АКАДЕМИЯ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ И СОЦИАЛЬНОГО РАЗВИТИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ (ГБОУ ВПО "НижГМА" МИНЗДРАВСОЦРАЗВИТИЯ РОССИИ) Method for prediction of life-threatening arrhythmias in patients with type 2 diabetes mellitus suffering chronic cardiac failure
US9119528B2 (en) 2012-10-30 2015-09-01 Dexcom, Inc. Systems and methods for providing sensitive and specific alarms
US10143426B2 (en) 2012-10-30 2018-12-04 Dexcom, Inc. Systems and methods for dynamically and intelligently monitoring a host's glycemic condition after an alert is triggered
US10555705B2 (en) 2012-10-30 2020-02-11 Dexcom, Inc. Systems and methods for dynamically and intelligently monitoring a host's glycemic condition after an alert is triggered
US10702215B2 (en) 2012-10-30 2020-07-07 Dexcom, Inc. Systems and methods for dynamically and intelligently monitoring a host's glycemic condition after an alert is triggered
US9655565B2 (en) 2012-10-30 2017-05-23 Dexcom, Inc. Systems and methods for dynamically and intelligently monitoring a host's glycemic condition after an alert is triggered
US11006903B2 (en) 2012-10-30 2021-05-18 Dexcom, Inc. Systems and methods for dynamically and intelligently monitoring a host's glycemic condition after an alert is triggered
US11026640B1 (en) 2012-10-30 2021-06-08 Dexcom, Inc. Systems and methods for dynamically and intelligently monitoring a host's glycemic condition after an alert is triggered
US11690577B2 (en) 2012-10-30 2023-07-04 Dexcom, Inc. Systems and methods for dynamically and intelligently monitoring a host's glycemic condition after an alert is triggered
US9119529B2 (en) 2012-10-30 2015-09-01 Dexcom, Inc. Systems and methods for dynamically and intelligently monitoring a host's glycemic condition after an alert is triggered
US11627894B2 (en) * 2014-07-17 2023-04-18 Roche Diabetes Care, Inc. Method and a device for determining a body fluid glucose level of a patient, and a computer program product

Similar Documents

Publication Publication Date Title
US20210361867A1 (en) Integrated closed-loop medication delivery with error model and safety check
US7874985B2 (en) Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data
US20190051410A1 (en) Glycemic risk determination based on variability of glucose levels
US6923763B1 (en) Method and apparatus for predicting the risk of hypoglycemia
CA2615575C (en) Systems, methods and computer program products for recognition of patterns of hyperglycemia in a user
Blevins et al. Statement by the American Association of Clinical Endocrinologists Consensus Panel on continuous glucose monitoring
Klonoff A review of continuous glucose monitoring technology
CA2394900C (en) Diabetes management system
AU2001251046A1 (en) Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data
EP2051620B1 (en) Method and device for monitoring a physiological parameter
Schaupp et al. Taking a closer look—continuous glucose monitoring in non-critically ill hospitalized patients with type 2 diabetes mellitus under basal-bolus insulin therapy
Schnipper et al. Society of Hospital Medicine Glycemic Control Task Force summary: practical recommendations for assessing the impact of glycemic control efforts
De Block et al. Randomized evaluation of glycemic control in the medical intensive care unit using real-time continuous glucose monitoring (REGIMEN Trial)
USH2246H1 (en) Method for analyzing continuous glucose monitoring data
CN110786865A (en) System and method for controlling blood glucose using personalized histograms
CA2382228A1 (en) Method and apparatus for predicting the risk of hypoglycemia
Price et al. The rationale for continuous glucose monitoring-based diabetes treatment decisions and non-adjunctive continuous glucose monitoring use
US20100106000A1 (en) Methods and Systems for Evaluating Glycemic Control
Rizvi et al. Assessment and monitoring of glycemic control in primary diabetes care: monitoring techniques, record keeping, meter downloads, tests of average glycemia, and point-of-care evaluation
US11793471B2 (en) Method and system for monitoring a diabetes treatment plan
Unnikrishnan et al. Suggested Protocols for Self-Monitoring of Blood Glucose in India
Munjal et al. Continuous Glucose Monitoring (CGM) Systems

Legal Events

Date Code Title Description
AS Assignment

Owner name: SANOFI-AVENTIS U.S. LLC, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MILLER, MICHAEL FRANKLIN;STRANGE, POUL;SIGNING DATES FROM 20070504 TO 20070507;REEL/FRAME:019268/0977

AS Assignment

Owner name: SANOFI-AVENTIS, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SANOFI-AVENTIS U.S. LLC.;REEL/FRAME:019293/0088

Effective date: 20070507

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: SANOFI, FRANCE

Free format text: CHANGE OF NAME;ASSIGNOR:SANOFI-AVENTIS;REEL/FRAME:026686/0522

Effective date: 20110511